短期（≤5 天）使用於緩解無法口服病人之中重度急性疼痛，通常使用於手術後。

Analgesic, Nonopioid; Nonsteroidal Anti-inflammatory Drug (NSAID), Oral; Nonsteroidal Anti-inflammatory Drug (NSAID), Parenteral

Onset of action: ~30 minutes.
Peak effect: ~2 to 3 hours.
Duration: 4 to 6 hours.
Distribution: Poor penetration into cerebrospinal fluid. Adults: 0.21 L/kg.
Protein binding: 99%.
Metabolism: Hepatic; undergoes hydroxylation and glucuronide conjugation.
Time to peak, serum: 1 to 3 minutes.
Excretion: Urine (92%, ~60% as unchanged drug); feces ~6%.

Hypersensitivity to ketorolac, aspirin, other nonsteroidal anti-inflammatory drugs (NSAIDs), or any component of the formulation; active or history of peptic ulcer disease, GI bleeding or perforation, asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs; renal disease; prophylactic analgesic before any major surgery; suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis, or high risk of bleeding; concurrent use with aspirin, other NSAIDs, probenecid, or pentoxifylline; use in the setting of coronary artery bypass graft surgery; labor and delivery.

Maternal use of NSAIDs should be avoided beginning at 20 weeks' gestation; Because NSAIDs may cause premature closure of the ductus arteriosus, prescribing information for ketorolac specifically states use should be avoided starting at 30 weeks' gestation

>10%: abdominal pain, dyspepsia, nausea, Increased liver enzymes (≤15%), headache.
1% to 10%: edema, hypertension, diaphoresis, pruritus, skin rash, constipation, diarrhea, flatulence, gastrointestinal fullness, gastrointestinal hemorrhage, gastrointestinal perforation, gastrointestinal ulcer, heartburn, stomatitis, vomiting, anemia, prolonged bleeding time, purpuric disease, pain at injection site (IM, IV), dizziness, drowsiness, tinnitus, renal function abnormality.

Migraine, severe, acute treatment (off-label use):
Weight ≥50 kg and <65 years of age: IV: 30 mg once.
Weight <50 kg or ≥65 years of age: IV: 15 mg once.
Pain management, acute:
Weight ≥50 kg and <65 years of age: IV: 30 mg as a single dose or 15 to 30 mg every 6 hours as needed; maximum daily dose: 120 mg/day; maximum duration: 5 days.
Weight <50 kg or ≥65 years of age: IV: 15 mg as a single dose or 15 mg every 6 hours as needed; maximum daily dose: 60 mg/day; maximum duration: 5 days.

Pain management (acute; moderately severe):
Infants and Children <2 years: 0.5 or 0.25 mg/kg/dose every 6 to 8 hours, not to exceed 48 to 72 hours of treatment; Maximum dose: 15 mg/dose.
Children ≥2 years and Adolescents ≤16 years: 0.5 mg/kg/dose every 6 to 8 hours; Maximum dose: 30 mg/dose, usual reported duration: 48 to 72 hours; not to exceed 5 days of treatment.

eGFR ≥60 mL/minute/1.73 m2: no dosage adjustment necessary.
eGFR >30 to <60 mL/minute/1.73 m2: use of analgesics other than nonsteroidal anti-inflammatory drugs may be preferred. If necessary, consider 7.5 to 15 mg every 6 hours.